UA116196C2 - Синтетичний міметик апеліну для лікування серцевої недостатності - Google Patents

Синтетичний міметик апеліну для лікування серцевої недостатності

Info

Publication number
UA116196C2
UA116196C2 UAA201408328A UAA201408328A UA116196C2 UA 116196 C2 UA116196 C2 UA 116196C2 UA A201408328 A UAA201408328 A UA A201408328A UA A201408328 A UAA201408328 A UA A201408328A UA 116196 C2 UA116196 C2 UA 116196C2
Authority
UA
Ukraine
Prior art keywords
treatment
heart failure
synthetic apelin
mimetics
apelin mimetics
Prior art date
Application number
UAA201408328A
Other languages
English (en)
Inventor
Андрєй Голосов
Філіпп Гроше
Ці-Йінг Ху
Хідетомо Імасе
Девід Томас Паркер
Кейо Ясошима
Фредерік Зекрі
Хонгджуань Чжао
Original Assignee
Новартіс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA116196(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартіс Аг filed Critical Новартіс Аг
Publication of UA116196C2 publication Critical patent/UA116196C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0816—Joints or connectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057—Pumps therefor
    • A61M16/0066—Blowers or centrifugal pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/201—Controlled valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)

Abstract

Винахід стосується поліпептиду формули Х1-R-P-R-X5-X6-X7-X8-X9-P-X11-X12-X13 або його аміду, складного ефіру або солі, де X1, Х5, Х6, Х7, Х8, Х9, X11, Х12 і X13 визначені в цьому описі. Даний поліпептид являє собою синтетичний міметик апеліну (агоніст APJ) для лікування серцевої недостатності. Винахід також стосується комбінації, що містить ефективну кількість поліпептиду, та один або декілька терапевтично активних співагентів, та фармацевтичної композиції, що містить даний поліпептид.
UAA201408328A 2012-01-27 2013-01-25 Синтетичний міметик апеліну для лікування серцевої недостатності UA116196C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261591557P 2012-01-27 2012-01-27
US201261717760P 2012-10-24 2012-10-24
US201261731697P 2012-11-30 2012-11-30
PCT/IB2013/050666 WO2013111110A2 (en) 2012-01-27 2013-01-25 Synthetic apelin mimetics for the treatment of heart failure

Publications (1)

Publication Number Publication Date
UA116196C2 true UA116196C2 (uk) 2018-02-26

Family

ID=47997598

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201408328A UA116196C2 (uk) 2012-01-27 2013-01-25 Синтетичний міметик апеліну для лікування серцевої недостатності

Country Status (43)

Country Link
US (4) US8673848B2 (uk)
EP (1) EP2807183B1 (uk)
JP (2) JP6313222B2 (uk)
KR (2) KR102068370B1 (uk)
CN (1) CN104220452B (uk)
AP (1) AP2014007846A0 (uk)
AR (1) AR089808A1 (uk)
AU (1) AU2013213265C1 (uk)
BR (1) BR112014018306A8 (uk)
CA (1) CA2862240A1 (uk)
CL (1) CL2014001994A1 (uk)
CO (1) CO7020879A2 (uk)
CR (1) CR20140364A (uk)
CU (1) CU24266B1 (uk)
CY (1) CY1120239T1 (uk)
DK (1) DK2807183T3 (uk)
EA (1) EA027853B1 (uk)
EC (1) ECSP14016014A (uk)
ES (1) ES2670832T3 (uk)
GT (1) GT201400166A (uk)
HK (1) HK1200470A1 (uk)
HR (1) HRP20180806T1 (uk)
HU (1) HUE039137T2 (uk)
IL (1) IL233792B (uk)
JO (1) JO3380B1 (uk)
LT (1) LT2807183T (uk)
MX (1) MX351569B (uk)
MY (1) MY172268A (uk)
NZ (1) NZ627772A (uk)
PE (1) PE20142194A1 (uk)
PH (1) PH12014501701A1 (uk)
PL (1) PL2807183T3 (uk)
PT (1) PT2807183T (uk)
RS (1) RS57200B1 (uk)
SG (1) SG11201404369PA (uk)
SI (1) SI2807183T1 (uk)
TN (1) TN2014000318A1 (uk)
TR (1) TR201807309T4 (uk)
TW (1) TWI576356B (uk)
UA (1) UA116196C2 (uk)
UY (1) UY34593A (uk)
WO (1) WO2013111110A2 (uk)
ZA (1) ZA201405400B (uk)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CN113007106B (zh) 2011-07-13 2023-08-11 费雪派克医疗保健有限公司 叶轮和马达组件
US8921307B2 (en) * 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
ES2732574T3 (es) 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
CN205515844U (zh) 2012-12-18 2016-08-31 费雪派克医疗保健有限公司 呼吸辅助装置以及用于电机的总成
JP6426107B2 (ja) * 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
CN105026423A (zh) * 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
US9908919B2 (en) * 2013-07-25 2018-03-06 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение
AU2014356126B2 (en) 2013-11-26 2017-01-05 Novartis Ag Methods for oxime conjugation to ketone-modified polypeptides
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
AU2015237357B2 (en) 2014-03-25 2019-04-18 Lanthiopep B.V. Cyclic apelin analogs
GB201407532D0 (en) 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
US10406198B2 (en) 2014-05-23 2019-09-10 Novartis Ag Methods for making conjugates from disulfide-containing proteins
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015200080A1 (en) 2014-06-23 2015-12-30 Novartis Ag Site specific protein modifications
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
MX2017009534A (es) * 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
USD790683S1 (en) * 2015-03-11 2017-06-27 Resmed Limited Pressurized air delivery console
ES2805743T3 (es) * 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
JP7063813B2 (ja) 2016-02-15 2022-05-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術後認知機能障害の処置のための方法及び医薬組成物
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
KR20190075968A (ko) 2016-10-19 2019-07-01 어바이브, 인크. 심혈관-관련 질환의 치료를 위한 아펠린의 신규 peg화 리포솜 제제
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11400247B2 (en) 2016-12-22 2022-08-02 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN114288513A (zh) 2017-04-23 2022-04-08 费雪派克医疗保健有限公司 呼吸辅助设备
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
AU2019378907A1 (en) 2018-11-14 2021-06-03 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (TPH1) for treating diseases or disorders associated with peripheral serotonin
EP3701992B1 (en) * 2019-02-27 2023-07-05 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Gas delivery device with deformable bag and differential pressure sensors
CN112007027B (zh) * 2020-09-14 2022-07-15 长春金赛药业有限责任公司 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0630405T3 (da) 1992-11-17 1999-01-04 Icos Corp Hidtil ukendt 7-transmembranreceptor benævnt V28
GB2281513B (en) * 1993-08-31 1997-12-03 Ulco Eng Pty Ltd Ventilator disconnect alarm
EP0645119A3 (en) * 1993-09-27 1998-04-15 Ohmeda Inc. Disabling apnoea volume software
US5598838A (en) * 1995-04-07 1997-02-04 Healthdyne Technologies, Inc. Pressure support ventilatory assist system
CA2222830C (en) * 1996-12-02 2004-03-30 Fisher & Paykel Limited Humidifier sleep apnea treatment apparatus
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
ATE383424T1 (de) 1997-12-24 2008-01-15 Takeda Pharmaceutical Polypeptide, deren herstellung und verwendung
AU5759399A (en) 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
WO2000020439A1 (fr) 1998-10-05 2000-04-13 Takeda Chemical Industries, Ltd. Procede d'elimination de methionine n-terminale
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
CN1419563A (zh) 2000-03-23 2003-05-21 武田药品工业株式会社 肽衍生物
AU2001264937A1 (en) 2000-05-23 2001-12-03 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
US6349724B1 (en) * 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
US7574368B2 (en) * 2000-12-15 2009-08-11 Ric Investments, Llc System and method for upgrading a pressure generating system
DE60230927D1 (de) 2001-07-16 2009-03-05 Caprotec Bioanalytics Gmbh Fangverbindungen, ihre entnahme und verfahren zur analysierung des proteoms und von komplexen zusammensetzungen
US7157035B2 (en) * 2001-12-14 2007-01-02 Fisher & Paykel Healthcare Limited Method of forming a respiratory conduit
TW545624U (en) * 2002-01-18 2003-08-01 Enermax Technology Corp Computer environment temperature/rotation speed display and self-adjusted fan speed device
WO2003063892A1 (fr) 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Utilisation d'apeline
US7086399B2 (en) * 2002-05-29 2006-08-08 Fisher & Paykel Healthcare Limited Apparatus for delivery of humidified gases therapy, associated methods and analysis tools
US7736646B2 (en) 2003-03-12 2010-06-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US7947280B2 (en) 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
US20050152836A1 (en) 2003-05-22 2005-07-14 Euan Ashley Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
EP1520861A1 (en) 2003-09-11 2005-04-06 Aventis Pharma Deutschland GmbH Test system for the identification of APJ receptor ligands
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
CN101035756A (zh) 2004-06-17 2007-09-12 南卡罗来纳州医科大学研究发展基金会 非天然氨基酸
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
JP2008013436A (ja) 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
WO2006047558A2 (en) 2004-10-26 2006-05-04 The General Hospital Corporation Methods for detecting a trial fibrillation and related conditions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US7736346B2 (en) 2005-10-18 2010-06-15 Biocardia, Inc. Bio-interventional therapeutic treatments for cardiovascular diseases
US20080031871A1 (en) 2006-02-21 2008-02-07 Allen Margaret L Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
US20090324610A1 (en) 2006-04-25 2009-12-31 Kyushu Univeristy, National University Corporation Gene associated with arteriosclerotic disease, and use thereof
US20100210559A1 (en) 2007-09-11 2010-08-19 Mondobiotech Laboratories Ag Trap-14 as a therapeutic agent
WO2009033819A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
US20110123534A1 (en) 2007-12-12 2011-05-26 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CN103396474A (zh) 2008-11-04 2013-11-20 安科治疗公司 Apj受体化合物
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
EP2496243A2 (en) 2009-11-04 2012-09-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2457216C1 (ru) 2010-12-21 2012-07-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) Додекапептиды, обладающие кардиопротекторными свойствами
CA2860740A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
US9908919B2 (en) 2013-07-25 2018-03-06 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca

Also Published As

Publication number Publication date
TN2014000318A1 (en) 2015-12-21
HUE039137T2 (hu) 2018-12-28
RS57200B1 (sr) 2018-07-31
ECSP14016014A (es) 2015-11-30
PL2807183T3 (pl) 2018-08-31
SG11201404369PA (en) 2014-08-28
TR201807309T4 (tr) 2018-06-21
CR20140364A (es) 2014-11-17
US8673848B2 (en) 2014-03-18
EA201491433A1 (ru) 2014-12-30
AU2013213265C1 (en) 2016-09-29
WO2013111110A2 (en) 2013-08-01
JO3380B1 (ar) 2019-03-13
KR102068370B1 (ko) 2020-01-21
MX351569B (es) 2017-10-19
AU2013213265B2 (en) 2016-05-26
CN104220452A (zh) 2014-12-17
US20170232221A1 (en) 2017-08-17
WO2013111110A3 (en) 2013-10-31
LT2807183T (lt) 2018-05-10
MY172268A (en) 2019-11-20
HRP20180806T1 (hr) 2018-06-29
EP2807183B1 (en) 2018-02-28
SI2807183T1 (en) 2018-05-31
US20140142022A1 (en) 2014-05-22
CA2862240A1 (en) 2013-08-01
DK2807183T3 (en) 2018-06-06
TWI576356B (zh) 2017-04-01
ZA201405400B (en) 2016-08-31
IL233792B (en) 2018-04-30
AP2014007846A0 (en) 2014-08-31
MX2014009085A (es) 2014-08-27
KR20140117603A (ko) 2014-10-07
CU24266B1 (es) 2017-07-04
CY1120239T1 (el) 2019-07-10
NZ627772A (en) 2015-11-27
UY34593A (es) 2013-09-02
ES2670832T3 (es) 2018-06-01
US9982017B2 (en) 2018-05-29
HK1200470A1 (en) 2015-08-07
BR112014018306A8 (pt) 2017-07-11
KR20200003229A (ko) 2020-01-08
GT201400166A (es) 2015-10-15
US20130196899A1 (en) 2013-08-01
CN104220452B (zh) 2018-01-26
EA027853B1 (ru) 2017-09-29
BR112014018306A2 (uk) 2017-06-20
EP2807183A2 (en) 2014-12-03
PT2807183T (pt) 2018-05-29
CU20140097A7 (es) 2015-03-30
CO7020879A2 (es) 2014-08-11
US9067971B2 (en) 2015-06-30
PE20142194A1 (es) 2014-12-21
JP2018048157A (ja) 2018-03-29
CL2014001994A1 (es) 2014-11-03
JP6595553B2 (ja) 2019-10-23
AR089808A1 (es) 2014-09-17
JP6313222B2 (ja) 2018-04-18
JP2015506370A (ja) 2015-03-02
PH12014501701A1 (en) 2014-10-13
US20150252076A1 (en) 2015-09-10
TW201335190A (zh) 2013-09-01
AU2013213265A1 (en) 2014-09-18
IL233792A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
HK1209323A1 (en) Esketamine for the treatment of treatment-refractory or treatment- resistant depression
PH12014501844B1 (en) Peptidomimetic macrocycles
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
MX359769B (es) Metodos para descelularizar huesos.
HK1204993A1 (en) Combination therapy for the treatment of glioblastoma
GB201219873D0 (en) Diverticulitis treatment
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
IN2014DN10209A (uk)
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
MX2015001134A (es) Compuestos terapeuticos.
UA72478U (uk) Застосування полентару як засобу фригопротекторної дії
UA79010U (uk) Застосування n-стеароїлетаноламіну як речовини з активною антигрипозною дією
AU335077S (en) Shoes
AU354730S (en) Roulette 73
UA58160U (uk) Застосування ліпофлавону як засобу для лікування гострої черепно-мозкової травми
AU352343S (en) Fitting for furniture
AU344542S (en) Lift brake
AU340267S (en) Kick scooters - stunt peg
UA80747U (uk) Застосування октенісепту як засобу для лікування метаепіфізарного остеомієліту
CL2012003477S1 (es) Perno de seguridad
UA106373C2 (uk) Застосування полентару як засобу фрігопротекторної дії